SOUTH
SAN FRANCISCO, Calif., June 1, 2023
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
today announced an upcoming poster presentation highlighting the
Company's IRAK1/4 program at the 2023 American Society of Clinical
Oncology (ASCO) Annual Meeting being held June 2-6, 2023, in Chicago, IL, and virtually.
Rigel continues to advance the open-label, Phase 1b clinical trial of R2891, an
investigational, potent, and selective IRAK1/4 inhibitor, in
patients with lower-risk myeloid dysplastic syndrome (LR-MDS) who
are refractory/resistant to prior therapies. Rigel has completed
enrollment of the first cohort of the trial and enrollment of the
second cohort is underway.
Poster Presentation Details:
Abstract #: TPS7085
Title: Phase 1b Clinical Study
of IRAK 1/4 Inhibition for Low-Risk Myelodysplastic Syndromes
Refractory/Resistant to Prior Therapies
Lead Author: Guillermo
Garcia-Manero, M.D., Professor, Chief Section MDS, Deputy
Chair Translational Medicine, Leukemia, University of Texas MD Anderson Cancer Center
Session Name: Hematologic Malignancies – Leukemia,
Myelodysplastic Syndromes, and Allotransplant
Date: June 5, 2023
Presentation Time: 8:00-11:00 AM
CDT
Location: Hall A
The conference abstract can be accessed here.
To learn more about Rigel Pharmaceuticals and the Company's
clinical and commercial hematology/oncology portfolio visit booth
#20134 during ASCO.
About R289
R289 is a prodrug of R8351, an
IRAK1/4 dual inhibitor, which has been shown in preclinical studies
to block inflammatory cytokine production in response to toll-like
receptor (TLR) and interleukin-1 receptor (IL-1R) family signaling.
TLRs and IL-1Rs play a critical role in the innate immune response
and dysregulation of these pathways can lead to various
inflammatory conditions. Chronic stimulation of both these receptor
systems is thought to cause the pro-inflammatory environment in the
bone marrow responsible for persistent cytopenias in lower-risk MDS
patients2.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
is a biotechnology company dedicated to discovering, developing and
providing novel therapies that significantly improve the lives of
patients with hematologic disorders and cancer. Founded in 1996,
Rigel is based in South San Francisco,
California. For more information on Rigel, the Company's
marketed products and pipeline of potential products, visit
www.rigel.com.
- R289 and R835 are investigational compounds not approved by the
FDA
- Sallman, DA et al. Unraveling the Pathogenesis of MDS: The
NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype.
Front Oncol. June 16, 2016. DOI:
https://doi.org/10.3389/fonc.2016.00151
Forward Looking Statements
This press release
contains forward-looking statements relating to, among other
things, that R289 may provide a meaningful benefit to people with
lower-risk myeloid dysplastic syndrome (LR-MDS) who are
refractory/resistant to prior therapies, our ability to further
develop R289, and our expectations related to the potential and
market opportunity of R289 as therapeutics for LR-MDS. Any
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Forward-looking statements can be identified by words such as
"plan", "potential", "may", "expects", "will" and similar
expressions in reference to future periods. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based on Rigel's current beliefs,
expectations, and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and
trends, the economy and other future conditions, and hence they
inherently involve significant risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Therefore, you should not
rely on any of these forward-looking statements. Actual results and
the timing of events could differ materially from those anticipated
in such forward looking statements as a result of these risks and
uncertainties, which include, without limitation, risks that the
FDA, EMA or other regulatory authorities may make adverse decisions
regarding R289; risks that clinical trials may not be predictive of
real-world results or of results in subsequent clinical trials;
risks that R289 may have unintended side effects, adverse reactions
or incidents of misuses; the availability of resources to develop
Rigel's product candidates; market competition; as well as other
risks detailed from time to time in Rigel's reports filed with the
Securities and Exchange Commission, including its Quarterly Report
on Form 10-Q for the quarter ended March 31,
2023 and subsequent filings. Any forward-looking statement
made by us in this press release is based only on
information currently available to us and speaks only as of the
date on which it is made. Rigel does not undertake any obligation
to update forward-looking statements, whether written or oral, that
may be made from time to time, whether as a result of new
information, future developments or otherwise, and expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein, except as required by law.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David
Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-announces-poster-presentation-at-the-upcoming-2023-american-society-of-clinical-oncology-annual-meeting-301839571.html
SOURCE Rigel Pharmaceuticals, Inc.